Anthem Biosciences IPO
Anthem Biosciences IPO — date, price band, lot size & details 2025
Anthem Biosciences listed on 21 Jul 2025 at ₹723.05, 26.9% above the ₹570 issue price.
Anthem Biosciences is a contract research, development and manufacturing company serving biotech and large pharmaceutical customers worldwide. It had 196 projects on 30 September 2024.
Stock price
Anthem Biosciences is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 10 November.
- Open 14 Jul 2025
- Close 16 Jul 2025
- Allotment 17 Jul 2025
- Refund/credit 18 Jul 2025
- Listing 21 Jul 2025
Issue summary
The terms of the offer, as filed.
| IPO Dates | 14 to 16 Jul, 2025 |
|---|---|
| Price Band | ₹540 – ₹570 |
| Face Value | ₹2 |
| Lot Size | 26 Shares |
| Issue Size | ₹3395 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Employee Discount | Rs 50.00 per share |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 14,820 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 26 shares at the ₹570 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 26 | ₹14,820 |
| Retail (max) | 13 | 338 | ₹1,92,660 |
| S-HNI (min) | 14 | 364 | ₹2,07,480 |
| S-HNI (max) | 67 | 1,742 | ₹9,92,940 |
| B-HNI (min) | 68 | 1,768 | ₹10,07,760 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Total income rose from Rs 1,133.99 crore in FY2023 to Rs 1,930.29 crore in FY2025.
- 02The EBITDA margin was 36.81% and the PAT margin was 23.38%.
- 03Total borrowing fell from Rs 232.53 crore on 31 March 2024 to Rs 108.95 crore on 31 March 2025.
- 04Return on equity was 20.82% and return on capital employed was 26.88%.
- 05The company had 196 projects on 30 September 2024.
Risks · 6
- 01The whole Rs 3,395 crore issue was offer for sale. The company got no fresh money.
- 02The P/E was 70.62 at the upper band of Rs 570, based on EPS of Rs 8.07.
- 03Profit after tax fell from Rs 385.19 crore in FY2023 to Rs 367.31 crore in FY2024 before rising in FY2025.
- 04Contract manufacturing income can be lumpy, and the company made ingredients for only 10 commercial molecules in the six months to 30 September 2024.
- 05Promoters held 76.87% before the issue and held 74.68% after it.
- 06Most customers are drug developers, so funding cycles in biotech can reduce the Rs 1,930.29 crore income base.
Three years of numbers
All figures in ₹ crore, as reported in the Anthem Biosciences offer document.
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Total Income | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax | 451.26 | 367.31 | 385.19 |
| EBITDA | 683.78 | 519.96 | 446.05 |
| NET Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves and Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowing | 108.95 | 232.53 | 125.06 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Anthem Biosciences RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Anthem Biosciences IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹8.07 | ₹8.07 |
| P/E Ratio (x) | 70.62 | 70.62 |
| Market Cap at Offer Price (₹ Cr) | ₹31,873.38 | ₹31,873.38 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹570 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Anthem Biosciences IPO will be updated shortly.
Anthem Biosciences IPO Anchor Investors
60 anchor investors across 41 fund houses committed ₹1,016.01 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
The company also makes fermentation-based active ingredients. These include probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
On 30 September 2024 it had 196 projects. In the six months to that date it made active ingredients and intermediates for ten commercial molecules, all supported since discovery.
The IPO was entirely an offer for sale of Rs 3,395 crore, so the company received no money from it.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Anthem Biosciences IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
JM Financial Ltd.
53 issues handledBest listing: Tempsens Instruments (India) (+111.3%). Weakest: Turtlemint Fintech Solutions (-10.4%).
JP Morgan India Pvt. Ltd
2 issues handled2 of their issues have listed so far, and 1 opened above the issue price (average -0.7%). That is too small a sample to read as a hit rate.
Citigroup Global Markets India Pvt. Ltd
4 issues handledBest listing: Hexaware Technologies (+5.3%). Weakest: Ajax Engineering (-8.4%).
Nomura Financial Advisory & Securities (India) Pvt. Ltd
3 issues handledBest listing: HDB Financial Services (+12.8%). Weakest: Kalpataru (0.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Anthem Biosciences?
The current Grey Market Premium is ₹170, or 30% over the issue price.
What is the Anthem Biosciences IPO price band?
₹540 to ₹570, on a face value of ₹2.
When is the allotment?
The basis of allotment is 17 July 2025, with listing on 21 July 2025.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
